SOX2 and neoplasm: The tumor initiation, maintenance and proliferation properties conferred by SOX2 may also introduce drug-resistance to CD133 (prominin-1) positive CSCs in GBM, making SOX2 a therapeutic target to treat the lethal brain cancer [17].